Literature DB >> 10779671

Towards an objective quantitative assessment of daily functioning in migraine: a feasibility study.

J H Tulen1, D L Stronks, J B Bussmann, L Pepplinkhuizen, J Passchier.   

Abstract

Migraine is a chronic disabling disorder, with migraine episodes significantly reducing quality of life and leading to impaired functioning (physically, socially, emotionally) both at home and at work. We explored whether ambulatory accelerometry can be used as an objective method to quantify the behavioral aspects of migraine-related disability. Four body mounted uni-axial piezo-resistive accelerometers were used to quantify the time spent in different body postures (lying, sitting, standing), physical activities (walking, cycling) and a general index of body motility during eight migraine attacks and subsequent recovery periods of six patients in their habitual environment. The migraine attacks and recovery periods could be monitored after about 1 h, which was the time required for the investigator to travel to the patient and for the sensors to be attached. In order to quantify the influence of a migraine episode on daily activities, we also performed measurements during a headache-free baseline period of the same patients. Overall, the procedures functioned well, indicating that ambulatory accelerometry measurements before, during and after a migraine attack are feasible to perform. Furthermore, our quantitative data revealed that migraine always influenced behavior by reducing overall body motility and that, dependent upon the severity of the attack, the effectiveness of acute treatment and the time of day, the time spent in various body positions, dynamic activities, and the number of postural transitions were affected. This feasibility study showed that ambulatory accelerometry can provide the objective behavioral effect parameters for the evaluation of migraine and its treatment on daily functioning in the habitual environment of migraine patients.

Entities:  

Mesh:

Year:  2000        PMID: 10779671     DOI: 10.1016/s0304-3959(00)00235-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

1.  Ambulatory measurement of upper limb usage and mobility-related activities during normal daily life with an upper limb-activity monitor: a feasibility study.

Authors:  F C Schasfoort; J B J Bussmann; H J Stam
Journal:  Med Biol Eng Comput       Date:  2002-03       Impact factor: 2.602

2.  Analysis of head movements coupled with trunk drift in healthy subjects.

Authors:  S Miyaoka; H Hirano; I Ashida; Y Miyaoka; Y Yamada
Journal:  Med Biol Eng Comput       Date:  2005-05       Impact factor: 2.602

3.  The Impact of Migraine Disease on Work Productivity and Quality of Life Among the Adults in Riyadh, Saudi Arabia.

Authors:  Rahaf F Alkahtani; Shawg S Alrumaih; Sarah S Algezlan; Rahaf R Almutairi; Basma A Alturki; Raghad M Alanazi; Fahad A Alateeq
Journal:  Cureus       Date:  2022-08-06

4.  Association between somatic amplification, anxiety, depression, stress and migraine.

Authors:  Burcu Goksan Yavuz; Elif Ilgaz Aydinlar; Pinar Yalinay Dikmen; Cem Incesu
Journal:  J Headache Pain       Date:  2013-06-25       Impact factor: 7.277

5.  Quality of life and migraine disability among female migraine patients in a tertiary hospital in Malaysia.

Authors:  Munvar Miya Shaik; Norul Badriah Hassan; Huay Lin Tan; Siew Hua Gan
Journal:  Biomed Res Int       Date:  2015-01-08       Impact factor: 3.411

6.  Wet Cupping Reduces Pain and Improves Health-related Quality of Life Among Patients with Migraine: A Prospective Observational Study.

Authors:  Abdullah Kaki; Rohaiem Sawsan; Mourad Samiha; Soad Al Jaouni; Mohsen Abdul Elalah; Nahla Ibrahim
Journal:  Oman Med J       Date:  2019-03

7.  Cortical spreading depolarisation-induced facial hyperalgesia, photophobia and hypomotility are ameliorated by sumatriptan and olcegepant.

Authors:  Chunhua Tang; Miyuki Unekawa; Satoshi Kitagawa; Tsubasa Takizawa; Yohei Kayama; Jin Nakahara; Mamoru Shibata
Journal:  Sci Rep       Date:  2020-07-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.